- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02900105
Effect of Letrozole on Seminal Parameters in Men With Non Obstructive Azoospermia and Severe Oligozoospermia.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a pilot study with recruitment carried out in a single centre where participants will be assigned to receive Letrozole 2.5 mg once a day for 4 months. The following data will be collected: semen analyses, clinical history including smoking status, BMI, Y microdeletion, karyotype and FSH, LH, testosterone, E2, drug side effects and effects on libido. The following assessments will be performed before and 4 months after drug administration: sperm analyses, FSH, LH, E2 and testosterone measurements.
Prior to recruitment, the study participant would have undergone the routine investigations for evaluating azoospermia or severe oligozoospermia. These would include FSH, LH, testosterone, karyotyping, Y chromosome microdeletion genetic studies and at least 1 seminal analysis. Despite the availability of biochemical techniques to differentiate non-obstructive azoospermia (NOA) patients from obstructive azoospermia patients, fine needle aspiration (FNA) has been regarded as a highly informative and a minimally invasive method often routinely done in the investigation of azoospermia. All patients with NOA would have a FNA performed as part of their routine workup which would be done before recruitment and initiation of Letrozole. The safety of FNA use is also regarded as being supportive for the researchers against any possible patient lawsuits resulting from any impaired spermatogenesis induced by an off-label prescription. All oligozoospermic patients will be offered to have their sperm cryopreserved before drug administration. The investigations must have been performed within a 6 month time frame prior to recruitment.
There will be 3 clinic visits during the dosing period and 1 post dosing follow up visit. During the initial visit where recruitment into the study occurs, the participant will be prescribed the medication. One week later, a telephone interview will be conducted to review for side effects and arrange an early appointment at patient request. One month later, the participant will be reviewed in clinic and a side effect check list will be conducted. Telephone interviews will be conducted again at 2nd and 3rd month from administration of the drug. At 4th month from administration of the drug, the blood tests and semen analysis will be performed. It is likely that the participant will still be followed up for enrolment into IVF / ICSI programme should spontaneous pregnancy fail to occur. The window period for all clinic visits and telephone interviews is +/- 5 days.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Singapore, Singapore, 229899
- KK Women's and Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Patients with non-obstructive azoospermia (absence of sperm in the pellets of two centrifuged semen samples collected 30-60 days apart)
- Patients with non-obstructive azoospermia who do not yield spermatozoa with fine needle aspiration (FNA)
- Patients with severe oligozoospermia (presence of sperm concentration less than 5 million per ml in both semen samples collected 30-60 days apart)
- Normal sperm appearance, consistency, liquefaction, volume and pH
- Patient must not possess any chromosomal aberrations
Exclusion Criteria
- Possible etiology of infertility present
- Seminal white blood cell concentration more than 10 million per ml
- Positive seminal culture analysis
- Positive urethral swab for chlamydia test
- Smoker
- Drug or alcohol abuse
- Ongoing medical treatment (gonadotropins, anabolic steroids, cancer chemotherapy, non-steroidal anti-inflammatory drugs, previous cancer radiotherapy or chemotherapy)
- Palpable varicocele
- X-ray exposure in the previous 8 months
- Y chromosome microdeletion
- Karyotype abnormalities (Klinefelter syndrome)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Letrozole
Participants will be assigned to receive Letrozole 2.5 mg once a day for 4 months
|
Letrozole 2.5mg (1 tablet) once a day for 4 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Sperm density
Time Frame: After 4 months dosage of Letrozole
|
After 4 months dosage of Letrozole
|
Sperm motility
Time Frame: After 4 months dosage of Letrozole
|
After 4 months dosage of Letrozole
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Total serum Testosterone level
Time Frame: After 4 months dosage of Letrozole
|
After 4 months dosage of Letrozole
|
Total serum Estradiol level
Time Frame: After 4 months dosage of Letrozole
|
After 4 months dosage of Letrozole
|
Total serum Follicle Stimulating Hormone level
Time Frame: After 4 months dosage of Letrozole
|
After 4 months dosage of Letrozole
|
Total serum Luteinizing Hormone level
Time Frame: After 4 months dosage of Letrozole
|
After 4 months dosage of Letrozole
|
Collaborators and Investigators
Investigators
- Principal Investigator: Shuling Liu, KK Women's and Children's Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infertility, Male
- Infertility
- Azoospermia
- Oligospermia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Letrozole
Other Study ID Numbers
- 2014/123/D
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Azoospermia, Nonobstructive
-
Acibadem UniversityCompletedAzoospermia, NonobstructiveTurkey
-
Hospices Civils de LyonNot yet recruitingAzoospermia, NonobstructiveFrance
-
Assiut UniversityUnknownAzoospermia, Nonobstructive
-
IRCCS San RaffaeleRecruiting
-
Cairo UniversityCompletedVaricocele | Azoospermia, NonobstructiveEgypt
-
Peking University Third HospitalCompletedInfertility, Male | Azoospermia, NonobstructiveChina
-
University of PittsburghInfertility and IVF Center, St. Louis, MOActive, not recruitingInfertility, Male | Azoospermia, NonobstructiveUnited States
-
Stanford UniversityRecruitingMale Infertility | Azoospermia | Nonobstructive AzoospermiaUnited States
Clinical Trials on Letrozole
-
Helsinki University Central HospitalFoundation for Paediatric Research, FinlandCompletedConstitutional Delay of Growth and PubertyFinland
-
Rovi Pharmaceuticals LaboratoriesRecruiting
-
Institut du Cancer de Montpellier - Val d'AurelleNovartisCompleted
-
University of Alabama at BirminghamGenentech, Inc.; Breast Cancer Research FoundationCompletedBreast Cancer | Breast Neoplasm | Cancer of the BreastUnited States
-
Fudan UniversityRecruitingEndometrial CancerChina
-
IVI MadridActive, not recruitingLuteinised Follicular CystSpain
-
Wyeth is now a wholly owned subsidiary of PfizerPfizerCompletedBreast Neoplasms
-
Assiut UniversityRecruitingInfertility, FemaleEgypt
-
Novartis PharmaceuticalsCompletedBreast NeoplasmUnited States, Germany, Spain, United Kingdom, France, Austria, Russian Federation, Italy, Canada, Belgium
-
Genor Biopharma Co., Ltd.Recruiting